Analytical goals for HbA1c: Are HbA1c results good enough for optimal use?

Journal of Diabetes

Volumn 3, Issue 1, 2011, Pages 3-6

  Little, Randie R ^a   Rohlfing, Curt L ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOASSAY; IRON DEFICIENCY ANEMIA; NOTE; PRIORITY JOURNAL; ARTICLE; BLOOD; CHEMICAL ANALYSIS; DIABETES MELLITUS; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD;

CHEMISTRY TECHNIQUES, ANALYTICAL; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79951781861     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2010.00109.x     Document Type: Note

References (19)

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-51.
3. 1c and the designated comparison methods in the United States, Japan, and Sweden. Clin Chem. 2008; 54: 1379-85.
4. 1c assay in the diagnosis of diabetes. [see comment]. Diabetes Care. 2009; 32: 1327-34.
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2010; 33: S11-61.
6. 1c measurement and goals for improvement: from Chaos to order for improving diabetes care. Clin Chem. DOI: 2010.148841.
7. College of American Pathologists. Surveys 2010 GH2-A Glycohemoglobin Participant Summary. Vol. College of American Pathologists, Nothfield (IL), 2010.
8. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
9. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. Available from: (Accessed September 2010).
10. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 1989; 27: 409-37.
11. Rohlfing C, Wiedmeyer HM, Little R et al. Biological variation of glycohemoglobin. Clin Chem. 2002; 48: 1116-8.
12. 1c in type 1 diabetes mellitus. Pediatr Int. 1999; 41: 357-62.
13. 1c) by 23 methods. Clin Chem. 2008; 54: 1277-82.
14. Mongia SK, Little RR, Rohlfing CL et al. Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays. Am J Clin Pathol. 2008; 130: 136-40.
15. 1c methods compared with the IFCC reference method. Am J Clin Pathol. 2008; 129: 811-4.
16. 1c assay interferences. Available from: (accessed November, 2010).
17. 1c levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008; 31: 1991-6.
18. 1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007; 30: 2453-7.
19. 1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94: 1689-94.